Compare Ryanair Holdings plc (RYAAY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Summit Therapeutics Inc — how do they compare? Ryanair Holdings plc trades at $59.4 (market cap $29.63B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Ryanair Holdings plc is far larger — about 2.5× Summit Therapeutics Inc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RYAAY | SMMT | |
|---|---|---|
Market Cap | $29.63B | $12.06B |
Sector | Industrials | Health |
52-Week High | $73.82 | $26.98 |
52-Week Low | $53.24 | $12.55 |
Enterprise Value | $26.61B | $11.39B |
Dividend Yield | 1.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $59.36, down 0.25% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and attractive valuation with a P/E of 14.37. Recent news highlights a strategic AI partnership with Google Cloud and industry challenges from lower fares and fuel costs.
The outlook is balanced; analyst consensus is bullish (62.5% buy ratings), but near-term headwinds from fare pressure and geopolitical risks persist. The stock offers value based on earnings, though operational volatility and competitive dynamics require monitoring for sustained growth.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
